Korro Bio, Inc. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Korro Bio, Inc. (KRRO) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $11.20 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-08-06
- 2026-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $11.20M.
- 2026-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $11.80M.
- 2025-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $13.40M.
- 2025-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $16.90M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2026-06-30 | $11.20M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $11.80M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $13.40M 10-K · filed 2026-03-12 |
| 2025-09-30 | $16.90M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $18.60M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $20.50M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $11.60M 10-K · filed 2025-03-18 |
| 2024-09-30 | $12.00M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $11.20M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $9.60M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $10.10M 10-K · filed 2024-03-26 |
| 2023-09-30 | $9.45M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $12.54M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $17.61M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $19.54M 10-K · filed 2023-03-10 |
| 2021-12-31 | $39.11M 10-K · filed 2023-03-10 |
| 2021-03-31 | $55.43M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $31.01M 10-K · filed 2022-03-15 |
| 2020-09-30 | $27.98M 10-Q · filed 2020-11-16 |
| 2020-06-30 | $29.40M 10-Q · filed 2020-08-12 |
| 2020-03-31 | $30.03M 10-Q · filed 2020-05-14 |
| 2019-12-31 | $13.82M 10-K · filed 2021-03-29 |
| 2019-09-30 | $6.33M 10-Q · filed 2019-11-18 |
| 2018-12-31 | $717.00K 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |